Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Randomized Phase II Study of R-CHOP-14 Versus R-CHOP-14 Followed By Chaser As Induction Therapy for High-Dose Chemotherapy (HDT), LEED, and Autologous Stem-Cell Transplantation (ASCT) in Poor-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Japan Clinical Oncology Group (JCOG) Study (JCOG0908)

Blood (2017) 130 (Supplement 1): 4127.

https://doi.org/10.1182/blood.V130.Suppl_1.4127.4127

Published: 2017

Journal Articles

FDC Like Cell Line HK With IL-2, IL-4 and OX40 Ligand Supports The Growth Of ATLL Cells

Yoshitoyo Kagami, MD, Dai Chihara, MD, Harumi Kato, M.D, Ph.D., Noriaki Yoshida, MD, Tomohiro Kinoshita, MD, PhD, Masao Seto, MD, PhD

Blood (2013) 122 (21): 4319.

https://doi.org/10.1182/blood.V122.21.4319.4319

Published: 2013

Journal Articles

Increased Peripheral T Cell Responses to EBV-Infected Cells with Frequent Detection of EBV-DNA In Plasma and Viral mRNA In Peripheral B-Cells In Immunocompetent EBV-Positive Diffuse Large B-Cell Lymphoma Patients

Satoko Morishima, MD, Kazuhito Yamamoto, MD, Hiroshi Kimura, MD, Seiko Iwata, MD, Tomohiro Kinoshita, MD, Hirokazu Nagai, MD, Isamu Sugiura, MD, Keitaro Tsushita, MD, Yoshitoyo Kagami, MD, Koichi Miyamura, MD, Kiyotaka Kuzushima, MD, Shigeo Nakamura, MD, Yasuo Morishima, MD

Blood (2010) 116 (21): 4163.

https://doi.org/10.1182/blood.V116.21.4163.4163

Published: 2010

Journal Articles

Cytotoxic Molecule (CM)-Positive Classical Hodgkin Lymphoma: a Clinicopathologic Study in Comparison with Nodal Peripheral T-Cell Lymphoma of Not Otherwise Specified Type Possessing CM Expression.

Naoko Asano, MD, PhD, Jun-Ichi Tamaru, MD, PhD, Fumihiro Ishida, MD, PhD, Tadashi Yoshino, MD, PhD, Yoshitoyo Kagami, MD, PhD, Yasuo Morishima, MD, PhD, Masao Seto, MD, PhD, Tomohiro Kinoshita, MD, PhD, Shigeo Nakamura, MD, PhD

Blood (2009) 114 (22): 1549.

https://doi.org/10.1182/blood.V114.22.1549.1549

Published: 2009

Journal Articles

Gastric Diffuse Large B-Cell Lymphoma: Analyses of Prognostic Factors and Value of Pretreatment FDG-PET Scan.

Dai Chihara, MD, Yasuhiro Oki, MD, Shouji Ine, MD, PhD, Hiroshi Onoda, MD, Harumi Kato, MD, Hirofumi Taji, MD, PhD, Yoshitoyo Kagami, MD, PhD, Kazuhito Yamamoto, MD, PhD, Yasuo Morishima, MD, PhD

Blood (2009) 114 (22): 3703.

https://doi.org/10.1182/blood.V114.22.3703.3703

Published: 2009

Journal Articles

Patterns of Relapse and Value of Follow up Procedures in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Who Achieve a Complete Remission (CR)

Yasuhiro Oki, Dai Chihara, Yoshitoyo Kagami, Shouji Ine, Harumi Kato, Hirofumi Taji, Kazuhito Yamamoto, Yasuo Morishima

Blood (2008) 112 (11): 5306.

https://doi.org/10.1182/blood.V112.11.5306.5306

Published: 2008

Journal Articles

Clinical Significance and Risk Factors of Delayed-Onset Neutropenia (DON) after Autologous Stem Cell Transplantation (ASCT) for B-Cell Non-Hodgkin Lymphoma: A Single-Institute Analysis.

Harumi Kato, MD, Keitaro Matsuo, MD, Kazuhito Yamamoto, MD, Yasuhiro Oki, MD, Chihiro Kondo, MD, Yoshitoyo Kagami, MD, Yasuo Morishima, MD

Blood (2007) 110 (11): 5111.

https://doi.org/10.1182/blood.V110.11.5111.5111

Published: 2007

Journal Articles

Low Serum Total Protein and Unfavorable Pathological Subtype Are Independent Unfavorable Factors in Peripheral T-Cell Lymphoma (PTCL) Treated in Prospective Clinical Tirals; Japan Clinical Oncology Group (JCOG) 0108A Study.

Yoshitoyo Kagami, MD, Tomohiro Kinoshita, MD, Takashi Watanabe, MD, Kuniaki Itoh, MD, Harumi Kaba, MSc, Kenichi Yoshimura, PhD, Motoko Yamaguchi, MD, Mitsutoshi Kurosawa, MD, Kunihiro Tsukasaki, MD, Masaharu Kasai, MD, Kensei Tobinai, MD, Yoshihiro Matsuno, MD, Kiyoshi Mukai, MD, Tomomitsu Hotta, MD, Masanori Shimoyama, MD

Blood (2007) 110 (11): 3450.

https://doi.org/10.1182/blood.V110.11.3450.3450

Published: 2007

Journal Articles

De Novo CD5 + Diffuse Large B-Cell Lymphoma: Result of a Detail Morphologic Evaluation and Long-Term Follow Up of 128 Patients.

Motoko Yamaguchi, MD, PhD, Naoya Nakamura, MD, PhD, Ritsuro Suzuki, MD, PhD, Yoshitoyo Kagami, MD, PhD, Masataka Okamoto, MD, PhD, Ryo Ichinohasama, MD, PhD, Tadashi Yoshino, MD, PhD, Junji Suzumiya, MD, PhD, Takuhei Murase, MD, PhD, Ikuo Miura, MD, PhD, Masami Hirano, MD, PhD, Yasuo Morishima, MD, PhD, Hiroshi Shiku, MD, PhD, Ryuzo Ueda, MD, PhD, Shigeo Nakamura, MD, PhD

Blood (2007) 110 (11): 1564.

https://doi.org/10.1182/blood.V110.11.1564.1564

Published: 2007

Journal Articles

Prognostic Value of Serum Soluble IL2 Receptor (sIL2R) Level in Patients with Diffuse Large B Cell Lymphoma (DLBCL), Treated with CHOP or R-CHOP Based Therapy.

Yasuhiro Oki, MD, Keitaro Matsuo, M.D., Ph.D., Harumi Kato, M.D., Kazuhito Yamamoto, M.D., Ph.D., Yoshitoyo Kagami, M.D., Ph.D., Yasuo Morishima, M.D., Ph.D.

Blood (2007) 110 (11): 1569.

https://doi.org/10.1182/blood.V110.11.1569.1569

Published: 2007

Journal Articles

Curable Potential with TBI Containing Regimen (L-PAM/TBI) Followed by In Vivo Purged Auto-PBSCT for Patients with Relapsed or Refractory Follicular Lymphoma.

Akane Tsujimura, Hirofumi Taji, Harumi Kato, Yoshitoyo Kagami, Kazuhito Yamamoto, Michinori Ogura, Yasuo Morishima

Blood (2006) 108 (11): 5440.

https://doi.org/10.1182/blood.V108.11.5440.5440

Published: 2006

Journal Articles

Peripheral T-Cell Lymphoma-Unspecified (PTCL-U) and NK/T-Cell Lymphoma Showed a Significantly Poor Prognosis in a Randomized Controlled Trial (RCT) JCOG9002 with Multidrug Combination Chemotherapy for Aggressive Lymphoma.

Tomohiro Kinoshita, MD, Tomomitsu Hotta, MD, Taro Shibata, MSc, Kiyoshi Mukai, MD, Motoko Yamaguchi, MD, Kunihiro Tsukasaki, MD, Yoshitoyo Kagami, MD, Masaharu Kasai, MD, Kensei Tobinai, MD, Masanori Shimoyama, MD

Blood (2006) 108 (11): 2465.

https://doi.org/10.1182/blood.V108.11.2465.2465

Published: 2006

Journal Articles

Validation Study on the Prediction of Response to Imatinib Mesylate in Chronic Myeloid Leukemia (CML) Patients by Genome-Wide cDNA Microarray Analysis.

Yoshitoyo Kagami, MD, PhD, Toyomasa Katagiri, PhD, Yasuyuki Kaneta, PhD, Takasi Tsuruo, PhD, Yusuke Nakamura, MD, PhD, Ryuzou Ohno, MD, PhD

Blood (2004) 104 (11): 2946.

https://doi.org/10.1182/blood.V104.11.2946.2946

Published: 2004

Journal Articles

Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles

Eisei Kondo, Yoshiki Akatsuka, Kiyotaka Kuzushima, Kunio Tsujimura, Shoji Asakura, Kohei Tajima, Yoshitoyo Kagami, Yoshihisa Kodera, Mitsune Tanimoto, Yasuo Morishima, Toshitada Takahashi

Blood (2004) 103 (2): 630–638.

https://doi.org/10.1182/blood-2003-03-0824

Published: 2004

Journal Articles

De novo CD5 + diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients

Motoko Yamaguchi, Masao Seto, Masataka Okamoto, Ryo Ichinohasama, Naoya Nakamura, Tadashi Yoshino, Junji Suzumiya, Takuhei Murase, Ikuo Miura, Takashi Akasaka, Jun-ichi Tamaru, Ritsuro Suzuki, Yoshitoyo Kagami, Masami Hirano, Yasuo Morishima, Ryuzo Ueda, Hiroshi Shiku, Shigeo Nakamura

Blood (2002) 99 (3): 815–821.

https://doi.org/10.1182/blood.V99.3.815

Published: 2002

Journal Articles

Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma

Keitaro Matsuo, Ritsuro Suzuki, Nobuyuki Hamajima, Michinori Ogura, Yoshitoyo Kagami, Hirofumi Taji, Eisei Kondoh, Satoko Maeda, Shoji Asakura, Sadayuki Kaba, Shigeo Nakamura, Masao Seto, Yasuo Morishima, Kazuo Tajima

Blood (2001) 97 (10): 3205–3209.

https://doi.org/10.1182/blood.V97.10.3205

Published: 2001

Journal Articles

Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype

Ritsuro Suzuki, Yoshitoyo Kagami, Kengo Takeuchi, Masahiro Kami, Masataka Okamoto, Ryo Ichinohasama, Naoyoshi Mori, Masaru Kojima, Tadashi Yoshino, Hirohiko Yamabe, Mami Shiota, Shigeo Mori, Michinori Ogura, Nobuyuki Hamajima, Masao Seto, Taizan Suchi, Yasuo Morishima, Shigeo Nakamura

Blood (2000) 96 (9): 2993–3000.

https://doi.org/10.1182/blood.V96.9.2993

Published: 2000

Journal Articles

CD7 + and CD56 + Myeloid/Natural Killer Cell Precursor Acute Leukemia: A Distinct Hematolymphoid Disease Entity

Ritsuro Suzuki, Kazuhito Yamamoto, Masao Seto, Yoshitoyo Kagami, Michinori Ogura, Yasushi Yatabe, Taizan Suchi, Yoshihisa Kodera, Yasuo Morishima, Toshitada Takahashi, Hidehiko Saito, Ryuzo Ueda, Shigeo Nakamura

Blood (1997) 90 (6): 2417–2428.

https://doi.org/10.1182/blood.V90.6.2417

Published: 1997

NARROW

Randomized Phase II Study of R-CHOP-14 Versus R-CHOP-14 Followed By Chaser As Induction Therapy for High-Dose Chemotherapy (HDT), LEED, and Autologous Stem-Cell Transplantation (ASCT) in Poor-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Japan Clinical Oncology Group (JCOG) Study (JCOG0908)

FDC Like Cell Line HK With IL-2, IL-4 and OX40 Ligand Supports The Growth Of ATLL Cells

Increased Peripheral T Cell Responses to EBV-Infected Cells with Frequent Detection of EBV-DNA In Plasma and Viral mRNA In Peripheral B-Cells In Immunocompetent EBV-Positive Diffuse Large B-Cell Lymphoma Patients

Cytotoxic Molecule (CM)-Positive Classical Hodgkin Lymphoma: a Clinicopathologic Study in Comparison with Nodal Peripheral T-Cell Lymphoma of Not Otherwise Specified Type Possessing CM Expression.

Gastric Diffuse Large B-Cell Lymphoma: Analyses of Prognostic Factors and Value of Pretreatment FDG-PET Scan.

Patterns of Relapse and Value of Follow up Procedures in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Who Achieve a Complete Remission (CR)

Clinical Significance and Risk Factors of Delayed-Onset Neutropenia (DON) after Autologous Stem Cell Transplantation (ASCT) for B-Cell Non-Hodgkin Lymphoma: A Single-Institute Analysis.

Low Serum Total Protein and Unfavorable Pathological Subtype Are Independent Unfavorable Factors in Peripheral T-Cell Lymphoma (PTCL) Treated in Prospective Clinical Tirals; Japan Clinical Oncology Group (JCOG) 0108A Study.

De Novo CD5 + Diffuse Large B-Cell Lymphoma: Result of a Detail Morphologic Evaluation and Long-Term Follow Up of 128 Patients.

Prognostic Value of Serum Soluble IL2 Receptor (sIL2R) Level in Patients with Diffuse Large B Cell Lymphoma (DLBCL), Treated with CHOP or R-CHOP Based Therapy.

Curable Potential with TBI Containing Regimen (L-PAM/TBI) Followed by In Vivo Purged Auto-PBSCT for Patients with Relapsed or Refractory Follicular Lymphoma.

Peripheral T-Cell Lymphoma-Unspecified (PTCL-U) and NK/T-Cell Lymphoma Showed a Significantly Poor Prognosis in a Randomized Controlled Trial (RCT) JCOG9002 with Multidrug Combination Chemotherapy for Aggressive Lymphoma.

Validation Study on the Prediction of Response to Imatinib Mesylate in Chronic Myeloid Leukemia (CML) Patients by Genome-Wide cDNA Microarray Analysis.

Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles

De novo CD5 + diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients

Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma

Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype

CD7 + and CD56 + Myeloid/Natural Killer Cell Precursor Acute Leukemia: A Distinct Hematolymphoid Disease Entity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only